Established in December 2000, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,600 collaborators from over 30 countries to improve the health of those in need – and to fulfill our dream that "every drug can be made and every disease can be treated."
Enabling more than 3,500 Innovative Collaborators from more than 30 Countries
Small Molecule Drug R&D and Manufacturing
Cell Therapy
and Gene Therapy
Drug R&D and Medical
Device Testing
Clinical
Services
Small Molecule Drug R&D and Manufacturing
To Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare Industry
WuXi AppTec Launches DNA Encoded Library (DEL) Service Package “DELight” to Expedite Early Drug Discovery
WuXi AppTec Reports First Half 2019 Interim Results
WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections
WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies
WuXi AppTec Acquires Pharmapace to Enhance Biometrics Services for Clinical Development
WuXi AppTec Announces Strong First-Quarter 2019 Results
